Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Common Stock Series B And D Preferred Stock	Common Stock Series E Preferred Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Non- Controlling Interest
Beginning balance at Dec. 31, 2020	$ 470,052		$ 129			$ 929,125	$ (467,878)		$ 0	$ 8,676
Beginning balance (in shares) at Dec. 31, 2020			1,288,596,000
Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise or vesting of equity awards (in shares)			91,080,000
Issuance of common stock upon exercise or vesting of equity awards	176		$ 9			167
Vesting of restricted stock - earnouts (in shares)			38,799,000
Vesting of restricted stock - earnouts	0		$ 4			(4)
Tax withholdings related to net share settlement of equity awards (in shares)			(797,000)
Tax withholdings related to net share settlement of equity awards	(9,463)					(9,463)
Founder shares repurchase	(24,998)					(24,998)
Founder shares repurchase (in shares)			(2,707,000)
Issuance of warrants to purchase Series D convertible preferred stock	300					300
Issuance of Series D and B convertible preferred stock upon exercise of warrants (in shares)				1,014,000	408,000
Issuance of common stock for a business acquisition (in shares)			1,634,000
Issuance of common stock for a business acquisition	15,160					15,160
Issuance of common stock upon reverse recapitalization, net of offering costs (Note 3) (in shares)			193,366,000
Issuance of common stock upon reverse recapitalization, net of offering costs (Note 3)	1,509,629		$ 19			1,509,610
Assumption of Public and Private Placement Warrants	(194,453)					(194,453)
Contributions from non-controlling interests	59,933									59,933
Stock-based compensation expense and other	1,579,400					1,579,400
Foreign currency translation	(1,715)								(1,715)
Net loss	(1,836,642)						(1,830,047)			(6,595)
Ending balance (in shares) at Dec. 31, 2021			1,611,393,000
Ending balance at Dec. 31, 2021	1,567,379	$ 5,195	$ 161			3,804,844	(2,297,925)	$ 5,195	(1,715)	62,014
Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise or vesting of equity awards (in shares)			124,651,000
Issuance of common stock upon exercise or vesting of equity awards	252		$ 13			239
Tax withholdings related to net share settlement of equity awards (in shares)			(296,000)
Tax withholdings related to net share settlement of equity awards	(981)					(981)
Issuance of common stock for a business acquisition (in shares)			114,517,000
Issuance of common stock for a business acquisition	279,745		$ 12			279,733
Issuance of common stock pursuant to public offering, net of issuance costs (in shares)			41,384,000
Issuance of common stock pursuant to public offering, net of issuance costs	98,910		$ 4			98,906
Issuance of common stock in exchange for services (in shares)			327,000
Issuance of common stock in exchange for services	1,000					1,000
Deconsolidation of subsidiaries	(55,408)									(55,408)
Acquisition of non-controlling interests	0					7,390				(7,390)
Stock-based compensation expense and other	1,947,474					1,945,247				2,227
Foreign currency translation	(917)								(917)
Net loss	$ (2,106,372)						(2,104,929)			(1,443)
Ending balance (in shares) at Dec. 31, 2022	1,891,976,000		1,891,976,000
Ending balance at Dec. 31, 2022	$ 1,736,277		$ 190			6,136,378	(4,397,659)		(2,632)	0
Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise or vesting of equity awards (in shares)			98,767,000
Issuance of common stock upon exercise or vesting of equity awards	555		$ 9			546
Tax withholdings related to net share settlement of equity awards (in shares)			(14,000)
Tax withholdings related to net share settlement of equity awards	(23)					(23)
Issuance of common stock for a business acquisition (in shares)			4,771,000
Issuance of common stock for a business acquisition	6,820					6,820
Issuance of common stock upon exercise of Public Warrants (in shares)			3,848,000
Settlement of contingent consideration	8,896					8,896
Issuance of common stock in exchange for services (in shares)			2,023,000
Issuance of common stock in exchange for services	$ 2,500					2,500
Forfeiture of restricted stock (in shares)	(56,000)
Stock-based compensation expense and other	$ 230,880					230,880
Foreign currency translation	4,116								4,116
Net loss	$ (892,869)						(892,869)			0
Ending balance (in shares) at Dec. 31, 2023	2,001,315,000		2,001,315,000
Ending balance at Dec. 31, 2023	$ 1,097,152		$ 199			$ 6,385,997	$ (5,290,528)		$ 1,484	$ 0